Managing haematology and oncology patients during the COVID ‐19 pandemic: interim consensus guidance
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: A pandemic coronavirus, SARS-CoV-2, causes COVID-19, a potentially life-threatening respiratory disease. Patients with cancer may have compromised immunity due to their malignancy and/or treatment, and may be at elevated risk of severe COVID-19. Community transmission of COVID-19 could overwhelm health care services, compromising delivery of cancer care. This interim consensus guidance provides advice for clinicians managing patients with cancer during the pandemic. MAIN RECOMMENDATIONS: During the COVID-19 pandemic: In patients with cancer with fever and/or respiratory symptoms, consider causes in addition to COVID-19, including other infections and therapy-related pneumonitis. For suspected or confirmed COVID-19, discuss temporary cessation of cancer therapy with a relevant specialist. Provide information on COVID-19 for patients and carers. Adopt measures within cancer centres to reduce risk of nosocomial SARS-CoV-2 acquisition; support population-wide social distancing; reduce demand on acute services; ensure adequate staffing; and provide culturally safe care. Measures should be equitable, transparent and proportionate to the COVID-19 threat. Consider the risks and benefits of modifying cancer therapies due to COVID-19. Communicate treatment modifications, and review once health service capacity allows. Consider potential impacts of COVID-19 on the blood supply and availability of stem cell donors. Discuss and document goals of care, and involve palliative care services in contingency planning. CHANGES IN MANAGEMENT AS A RESULT OF THIS STATEMENT: This interim consensus guidance provides a framework for clinicians managing patients with cancer during the COVID-19 pandemic. In view of the rapidly changing situation, clinicians must also monitor national, state, local and institutional policies, which will take precedence. ENDORSED BY: Australasian Leukaemia and Lymphoma Group; Australasian Lung Cancer Trials Group; Australian and New Zealand Children's Haematology/Oncology Group; Australia and New Zealand Society of Palliative Medicine; Australasian Society for Infectious Diseases; Bone Marrow Transplantation Society of Australia and New Zealand; Cancer Council Australia; Cancer Nurses Society of Australia; Cancer Society of New Zealand; Clinical Oncology Society of Australia; Haematology Society of Australia and New Zealand; National Centre for Infections in Cancer; New Zealand Cancer Control Agency; New Zealand Society for Oncology; and Palliative Care Australia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults
Xia, W., Shao, J., Guo, Y., Peng, X., Li, Z., & Hu, D. (2020) · Pediatric Pulmonology · doi:10.1002/ppul.24718 · Cited by 1,057
AGREE II: advancing guideline development, reporting, and evaluation in health care
Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Grimshaw, J., Hanna, S. E., et al. (2010) · Preventive Medicine · doi:10.1016/j.ypmed.2010.08.005 · Cited by 758
Research works printed but not linked: 50
- 10.1001/jama.2020.2648 · DOI · Paper page
- 10.1093/cid/cis844 · DOI · Paper page
- 10.1001/jama.2020.1585 · DOI · Paper page
- 10.1016/S1470-2045(20)30096-6 · DOI · Paper page
- 10.1016/S1470-2045(20)30150-9 · DOI · Paper page
- 10.1016/S1470-2045(20)30149-2 · DOI · Paper page
- 10.1038/s41409-018-0386-z · DOI
- 10.1056/NEJMoa2002032 · DOI · Paper page
- 10.1016/S0140-6736(20)30183-5 · DOI · Paper page
- 10.1016/S0140-6736(20)30566-3 · DOI · Paper page
- 10.1007/s00247-020-04656-7 · DOI · Paper page
- 10.1016/S0924-8579(00)00241-7 · doi:10.1016/s0924-8579(00)00241-7
- 10.1097/INF.0000000000002660 · DOI · Paper page
- 10.1016/S0140-6736(20)30154-9 · DOI · Paper page
- Chen Z, 2020, COVID-19 with post-chemotherapy agranulocytosis in childhood acute leukemia: a case report, Zhonghua Xue Ye Xue Za Zhi, 41, E004
- 10.1371/journal.pone.0170774 · DOI
- 10.1001/jama.2020.3204 · DOI · Paper page
- 10.1016/S1470-2045(20)30096-6 · DOI · Paper page
- 10.1093/jpids/pix093 · DOI · Paper page
- 10.1016/S0002-9343(97)00003-X · DOI · Paper page
- 10.1016/j.jcv.2015.04.012 · doi:10.1016/j.jcv.2015.04.012
- Cancer Australia, Optimal care pathway for Aboriginal and Torres Strait Islander people with cancer
- Medical Council of New Zealand, 2019, Statement on cultural competence and the provision of culturally-safe care
- 10.1001/jama.2020.4031 · DOI · Paper page
- Medical Council of New Zealand, 2018, Safe practice in an environment of resource limitation
- Australian Government Department of Health, 2020, Australian health sector emergency response plan for novel coronavirus (COVID-19)
- 10.1186/s12885-016-2781-4 · DOI
- 10.1016/S1470-2045(08)70150-5 · DOI · Paper page
- 10.1097/01.inf.0000254148.09831.7f · DOI
- 10.1111/trf.14370 · DOI
- 10.1016/j.tmrv.2020.02.003 · DOI · Paper page
- World Health Organization, 2019, Protecting the blood supply during infectious disease outbreaks. guidance for national blood services
- 10.1001/jama.2019.0554 · DOI · Paper page
- 10.1111/imj.13434 · doi:10.1111/imj.13434
- 10.1111/bjh.16347 · DOI
- Carson JL, 2016, Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion, Cochrane Database Syst Rev, CD002042
- 10.1136/bmj.i1351 · DOI · Paper page
- 10.1056/NEJMoa1212772 · DOI · Paper page
- 10.1111/bjh.14423 · DOI · Paper page
- Estcourt LJ, 2019, The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled trial, Trials, 20, 592, 10.1186/s13063-019-3663-2 · doi:10.1186/s13063-019-3663-2
- 10.1093/cid/civ272 · DOI
- 10.1182/blood-2013-12-541359 · doi:10.1182/blood-2013-12-541359
- 10.1016/j.bbmt.2015.11.015 · DOI
- Australasian Bone Marrow Transplant Recipient Registry, 2018, Annual data summary 2018
- 10.1038/s41409-020-0873-x · doi:10.1038/s41409-020-0873-x
- 10.1016/j.ctro.2020.03.009 · DOI · Paper page
- 10.1046/j.0004-8461.2003.01165.x · DOI
- Therapeutic Goods Administration, 2018, ICH guideline for good clinical practice
- 10.1016/j.jpainsymman.2009.11.241 · DOI · Paper page
- 10.1191/0269216304pm859oa · DOI · Paper page
Cited by
Al-Shamsi, H. O., Alhazzani, W., Alhuraiji, A., Coomes, E. A., Chemaly, R. F., Almuhanna, M., Wolff, R. A., Ibrahim, N. K., Chua, M. L. K., Hotte, S. J., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0213 · Cited by 694
Bhaskar, S., Sinha, A., Banach, M., Mittoo, S., Weissert, R., Kass, J. S., Rajagopal, S., Pai, A. R., & Kutty, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01648 · Cited by 511
Paterson, C., Bacon, R., Dwyer, R., Morrison, K. S., Toohey, K., O'Dea, A., Slade, J., Mortazavi, R., Roberts, C., Pranavan, G., et al. (2020) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2020.151090 · Cited by 139
Cancer survivorship care at the time of the COVID ‐19 pandemic
Koczwara, B. (2020) · Medical Journal of Australia · doi:10.5694/mja2.50684 · Cited by 22
Yildiz Kabak, V., Atasavun Uysal, S., & Duger, T. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-020-05965-1 · Cited by 19
Metadata
- Authors
- Weinkove, R., McQuilten, Z. K., Adler, J., Agar, M. R., Blyth, E., Cheng, A. C., Conyers, R., Haeusler, G. M., Hardie, C., Jackson, C., Lane, S. W., Middlemiss, T., Mollee, P., Mulligan, S. P., Ritchie, D., Ruka, M., Solomon, B., Szer, J., Thursky, K. A., Wood, E. M., Worth, L. J., Yong, M. K., Slavin, M. A., & Teh, B. W.
- Venue
- Medical Journal of Australia
- Publisher
- Wiley
- Published
- 2020-05-13
- Volume
- 212
- Issue
- 10
- Pages
- 481-489
- ISSN
- 0025-729X (ISSN-L)
- 1326-5377
- OpenAlex
- W3012421643
- Cited by
- 123
- References
- 2
- FWCI
- 9.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- onlinelibrary.wiley.com/termsAndConditions#vor (vor)
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.